Recently, a meta-analysis consisting of 12 randomized controlled trials (RCTs) and involving 911 patients revealed that the BHD could be an adjunct therapy with RAAS inhibitors for early diabetic nephropathy patients by reducing the 24 h urine albumin excretion rate (UAER) [21]. Here, ALB is linked to diabetic kidney disease.